Development and in vitro evaluation of pH-independent release matrix tablet of weakly acidic drug valsartan using quality by design tools

References

• ICH. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, Pharmaceutical development Q8 (R2). ICH Harmon. Tripart. Guidel. 2009.
   Google Scholar
• Juran JM, Godfrey AB. Juran’s quality control handbook. New York (NY): McGraw-Hill. 1998.
   Google Scholar
• ICH. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, Quality Risk Management Q9. ICH Harmon. Tripart. Guidel. 2005.
   Google Scholar
• Dashevsky A, Kolter K, Bodmeier R. pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoat SR 30 D and the enteric polymer dispersion Kollicoat MAE 30 DP. Eur J Pharm Biopharm. 2004;58:45–49.
   PubMed Web of Science ®Google Scholar
• Takeuchi S, Tsume Y. The Successful Assessment of Bioequivalence of a BCS Class IIa Drug by Gastrointestinal Simulator [Internet]. 2015. Available from: http://abstracts.aaps.org/verify/aaps2015/postersubmissions/t2079.pdfhttp://abstracts.aaps.org/verify/aaps2015/postersubmissions/t2079.pdf.
   Google Scholar
• Markham A, Goa KL. Valsartan a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997;54:299–311.
   PubMed Web of Science ®Google Scholar
• Saydam M, Takka S. Bioavailability file: Valsartan. Fabad J Pharm Sci. 2007;32:185–196.
   Google Scholar
• Schmidt EK, Antonin KH, Flesch G, et al. An interaction study with cimetidine and the new angiotensin II antagonist valsartan. Eur J Clin Pharmacol. 1998;53:451–458.
   PubMed Web of Science ®Google Scholar
• Saydam M. Association of QbD Tools with Biopharmaceutical Classification Systems. ISPE Pharm Eng. 2016;March–April:78–82.
   Google Scholar
• Anurag S, Stephen H, Stephen M. Quality by design: industrial case studies on defining and implementing design space for pharmaceutical processes (Part 2). BioPharm Int. 2009;22:37–42.
   Web of Science ®Google Scholar
• Pharmacopeia United States. USP General Chapter 〈711〉 Dissolution. Rockville (MD): US Pharmacopeial Conv. United B. Press; 2011. p. 1–8.
   Google Scholar
• FDA. Food and drug administration, quality by design for andas: an example for modified-release dosage forms. Silver Spring (MD): FDA; 2011.
   Google Scholar
• Dash S, Murthy PN, Nath L, et al. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm. 2010;67:217–223.
   PubMed Web of Science ®Google Scholar
• Ramteke KH, Dighe PA, Kharat AR, et al. Mathematical models of drug dissolution: a review. Sch Acad J Pharm. 2014;3:388–396.
   Google Scholar
• Hixson AW, Crowell JH. Dependence of reaction velocity upon surface agitation. Ind Eng Chem. 1931;23:923–931.
   Google Scholar
• Higuchi T. Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci. 1961;50:874–875.
   PubMed Web of Science ®Google Scholar
• Higuchi T. Mechanism of sustained‐action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149.
   PubMed Web of Science ®Google Scholar
• Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 1989;57:169–172.
   Web of Science ®Google Scholar
• Costa P, Lobo JMS. Influence of dissolution medium agitation on release profiles of sustained-release tablets. Drug Dev Ind Pharm. 2001;27:811–817.
   PubMed Web of Science ®Google Scholar
• Chudiwal VS, Shahi S, Chudiwal S. Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach. Drug Dev Ind Pharm. 2018;44:787–799.
   PubMed Web of Science ®Google Scholar
• Rao VM, Engh K, Qiu Y. Design of pH-independent controlled release matrix tablets for acidic drugs. Int J Pharm. 2003;252:81–86.
   PubMed Web of Science ®Google Scholar
• Tukaram BN, Rajagopalan IV, Shartchandra PSI. The effects of lactose, microcrystalline cellulose and dicalcium phosphate on swelling and erosion of compressed HPMC matrix tablets: texture analyzer. Iran J Pharm Res. 2010;9:349–358.
   PubMed Web of Science ®Google Scholar
• Wadher KJ, Kakde RB, Umekar MJ. Formulation and evaluation of sustained release tablets of metformin hydrochloride by solid dispersion technique using pH dependent and pH independent eudragit polymers. Br J Pharm Res. 2011;1:29–45.
   Google Scholar
• Phadtare D, Phadtare G, Asawat M. Hypromellose- a choice of polymer in extended release tablet formulation. World J Pharm Pharm Sci. 2014;3:551–566.
   Google Scholar
• Qui Y. Rational design of oral modified-release drug delivery systems. In: Qui Y, Chen Y, Zhang G, editors. Dev Solid Oral Dos Forms Pharm Theory Pract. 1st ed. New York: Elsevier Inc.; 2009. p. 469–499.
   Google Scholar
• Riis T, Bauer-Brandl A, Wagner T, et al. pH-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm. 2007;65:78–84.
   PubMed Web of Science ®Google Scholar
• Pygall SR, Kujawinski S, Timmins P, et al. Mechanisms of drug release in citrate buffered HPMC matrices. Int J Pharm. 2009;370:110–120.
   PubMed Web of Science ®Google Scholar
• Lee KR, Kim EJ, Seo SW, et al. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine. Arch Pharm Res. 2008;31:1023–1028.
   PubMed Web of Science ®Google Scholar
• Manvi P, Narendra P, Bhaskar VH. Preperation, characterization and in vitro evaluation of repaglinide binary solid dispersions with hydrophilic polymers. Int J Drug Dev Res. 2011;3:107–117.
   Google Scholar
• Fule R, Amin P. Development and evaluation of lafutidine solid dispersion via hot melt extrusion: Investigating drug-polymer miscibility with advanced characterisation. Asian J Pharm Sci. 2014;9:92–106.
   Google Scholar
• Criscione L, Bradley WA, Buhlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-i1 antagonist. Cardiovasc Drug Rev. 1995;13:230–250.
   Web of Science ®Google Scholar
• Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm. 2001;52:75–82.
   PubMed Web of Science ®Google Scholar